NASDAQ:MASI Masimo - MASI Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Masimo Co. Please log in to your account or sign up in order to add this asset to your watchlist. $169.45 -5.27 (-3.02%) (As of 02/3/2023 12:00 AM ET) Add Compare Share Share Today's Range$168.49▼$173.6050-Day Range$138.49▼$174.7252-Week Range$108.89▼$237.85Volume402,161 shsAverage Volume422,674 shsMarket Capitalization$8.91 billionP/E Ratio56.11Dividend YieldN/APrice Target$188.00 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability Masimo MarketRank™ ForecastAnalyst RatingModerate Buy2.88 Rating ScoreUpside/Downside10.9% Upside$188.00 Price TargetShort InterestHealthy2.99% of Float Sold ShortDividend StrengthN/ASustainability-0.86Upright™ Environmental ScoreNews Sentiment0.29Based on 6 Articles This WeekInsider TradingAcquiring Shares$5.99 M Bought Last QuarterProj. Earnings Growth-1.80%From $4.44 to $4.36 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.48 out of 5 starsMedical Sector142nd out of 1,025 stocksElectromedical Equipment Industry2nd out of 24 stocks 2.4 Analyst's Opinion Consensus RatingMasimo has received a consensus rating of Buy. The company's average rating score is 2.88, and is based on 7 buy ratings, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $188.00, Masimo has a forecasted upside of 10.9% from its current price of $169.45.Amount of Analyst CoverageMasimo has only been the subject of 4 research reports in the past 90 days. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.99% of the float of Masimo has been sold short.Short Interest Ratio / Days to CoverMasimo has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Masimo has recently decreased by 5.19%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldMasimo does not currently pay a dividend.Dividend GrowthMasimo does not have a long track record of dividend growth. Previous Next 4.2 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMasimo has received a 61.97% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "ECG monitors" product. See details.Environmental SustainabilityThe Environmental Impact score for Masimo is -0.86. Previous Next 2.4 News and Social Media Coverage News SentimentMasimo has a news sentiment score of 0.29. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.47 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Masimo this week, compared to 5 articles on an average week.Search Interest8 people have searched for MASI on MarketBeat in the last 30 days. This is an increase of 60% compared to the previous 30 days.MarketBeat FollowsOnly 12 people have added Masimo to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Masimo insiders have bought more of their company's stock than they have sold. Specifically, they have bought $5,992,495.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 9.70% of the stock of Masimo is held by insiders.Percentage Held by Institutions87.67% of the stock of Masimo is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Masimo are expected to decrease by -1.80% in the coming year, from $4.44 to $4.36 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Masimo is 56.11, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 137.51.Price to Earnings Ratio vs. SectorThe P/E ratio of Masimo is 56.11, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 114.73.Price to Book Value per Share RatioMasimo has a P/B Ratio of 6.05. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Masimo (NASDAQ:MASI) StockMasimo Corp. is a medical technology company, which develops, manufactures and markets noninvasive patient monitoring technologies, medical devices and sensors. Its products include continuous monitors, patient-worn monitors, hospital automation connectivity, capnography & gas, data download & analytics and sensors & accessories. The company was founded by Joe E. Kiani in May 1989 and is headquartered in Irvine, CA.Read More Receive MASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Masimo and its competitors with MarketBeat's FREE daily newsletter. Email Address MASI Stock News HeadlinesFebruary 4, 2023 | americanbankingnews.comMasimo Co. (NASDAQ:MASI) Receives $188.00 Average Price Target from AnalystsFebruary 2, 2023 | investing.comHedge fund lobby group supports shareholder rights in Masimo caseFebruary 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 30, 2023 | finance.yahoo.comMasimo Announces the Limited Market Release of Visual Clinical Activity Monitoring (VCAM™)January 29, 2023 | marketwatch.comNewborn Screening Instruments Market : Projections and Regional Outlook, Set for Rapid Growth and Trend by 2023 To 2028January 23, 2023 | finance.yahoo.comResearchers Harness the Power of Masimo Root®’s Advanced Multimodal Monitoring Capabilities to Study the Impact of Different Ventilatory Strategies on Brain Oxygenation During Thoracoscopic SurgeryJanuary 18, 2023 | finance.yahoo.comMasimo and Philips Expand Partnership to Improve Telehealth for Patients and Clinicians Around the World with the Masimo W1™ WatchJanuary 16, 2023 | finance.yahoo.comShould You Hold Masimo Corporation (MASI)?February 5, 2023 | Investor Place Media (Ad)Cash Holders STILL Aren't Taking Steps to PrepareStocks are crashing... inflation is through the roof... multiple industries are getting hit hard... Americans are fearful of what might happen to their stock portfolios right now -- and who's to blame them? But former Wall Street money manager Louis Navellier says all it takes is being on the right side of this force driving the massive divide. Take action today and watch his exclusive presentation -- absolutely free of charge -- to see how you should be prepping for this phenomenon.January 11, 2023 | finance.yahoo.comHow Masimo Is Taking On Electronics Giant Apple — And WinningJanuary 11, 2023 | investing.comMasimo gains as judge rules Apple Watch infringed its patent, seen as a positive signalJanuary 10, 2023 | finance.yahoo.comITC Judge Rules Apple Violated U.S. Trade Laws by Infringing Masimo Pulse Oximeter PatentJanuary 9, 2023 | finance.yahoo.comNew Study Evaluates the Performance of Masimo SpHb® Noninvasive Spot-Check Hemoglobin in the Emergency DepartmentJanuary 5, 2023 | marketwatch.comPulse Oximetry Market Expands its Automatic Reporting for Movement Data with Detailed Tables and Figures, Analytical Research Report to 2028January 5, 2023 | finance.yahoo.comNew Study Finds That Masimo Patient SafetyNet™ Helped Clinicians Reduce CPR Events and Rates, Improve CPR Success Rate, and Reduce Hospital Length of Stay and MortalityJanuary 4, 2023 | finance.yahoo.comMasimo to Present in 41st Annual J.P. Morgan Healthcare ConferenceJanuary 3, 2023 | seekingalpha.comMasimo: Premium Valuations Have Priced In Long-Term Growth PotentialJanuary 3, 2023 | finance.yahoo.comNew Prospective Study Evaluates the Accuracy of Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring During Elective Cesarean SectionDecember 26, 2022 | finance.yahoo.comWhat Is Masimo Corporation's (NASDAQ:MASI) Share Price Doing?December 13, 2022 | finance.yahoo.comMasimo Takes Major Step in Connecting the Hospital to the HomeDecember 13, 2022 | finance.yahoo.comMasimo Hosts Investor Day to Detail Next Phase of Its Growth TrajectoryDecember 12, 2022 | finance.yahoo.comMasimo Announces Limited Market Release of Sepsis IndexDecember 7, 2022 | msn.comMasimo's Return On Capital Employed OverviewDecember 7, 2022 | finance.yahoo.comMasimo Announces Full Market Release of Hydration Index for the Masimo W1™ Advanced Health Tracking WatchDecember 3, 2022 | finance.yahoo.comDo Its Financials Have Any Role To Play In Driving Masimo Corporation's (NASDAQ:MASI) Stock Up Recently?November 30, 2022 | finance.yahoo.comNew Prospective Study Finds That Masimo SpHb® Noninvasive and Continuous Hemoglobin Monitoring Can Help Provide Effective Blood Management in Patients Undergoing Major SurgeryNovember 29, 2022 | finance.yahoo.comH2O: the FT investigation’s big finaleSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive MASI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Masimo and its competitors with MarketBeat's FREE daily newsletter. Email Address MASI Company Calendar Last Earnings11/08/2022Today2/05/2023Next Earnings (Estimated)2/21/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Electromedical equipment Sub-IndustryHealth Care Equipment SectorMedical Current SymbolNASDAQ:MASI CUSIP57479510 CIK937556 Webwww.masimo.com Phone(949) 297-7000Fax949-297-7001Employees6,200Year Founded1989Price Target and Rating Average Stock Price Forecast$188.00 High Stock Price Forecast$295.00 Low Stock Price Forecast$135.00 Forecasted Upside/Downside+10.9%Consensus RatingModerate Buy Rating Score (0-4)2.88 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)$3.02 Trailing P/E Ratio56.11 Forward P/E Ratio38.16 P/E GrowthN/ANet Income$229.65 million Net Margins9.78% Pretax Margin12.28% Return on Equity18.04% Return on Assets10.27% Debt Debt-to-Equity Ratio0.76 Current Ratio2.12 Quick Ratio1.28 Sales & Book Value Annual Sales$1.24 billion Price / Sales7.19 Cash Flow$4.80 per share Price / Cash Flow35.27 Book Value$28.00 per share Price / Book6.05Miscellaneous Outstanding Shares52,560,000Free Float47,466,000Market Cap$8.91 billion OptionableOptionable Beta0.87 Social Links Key ExecutivesJoe E. KianiChairman & Chief Executive OfficerBilal MuhsinChief Operating OfficerMicah YoungChief Financial Officer & Executive Vice PresidentYongsam LeeChief Information Officer & Executive VPAnand SampathExecutive VP-Operations & Clinical ResearchKey CompetitorsCONMEDNYSE:CNMDInModeNASDAQ:INMDLivaNovaNASDAQ:LIVNDr. Reddy's LaboratoriesNYSE:RDYagilon healthNYSE:AGLView All CompetitorsInsiders & InstitutionsIllinois Municipal Retirement FundSold 3,123 shares on 2/3/2023Ownership: 0.018%Archer Investment CorpBought 159 shares on 2/3/2023Ownership: 0.001%Ascent Wealth Partners LLCBought 242 shares on 2/2/2023Ownership: 0.030%ProShare Advisors LLCBought 301 shares on 2/2/2023Ownership: 0.007%Profund Advisors LLCBought 87 shares on 2/2/2023Ownership: 0.004%View All Insider TransactionsView All Institutional Transactions MASI Stock - Frequently Asked Questions Should I buy or sell Masimo stock right now? 8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Masimo in the last twelve months. There are currently 1 hold rating and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" MASI shares. View MASI analyst ratings or view top-rated stocks. What is Masimo's stock price forecast for 2023? 8 brokers have issued 1 year price objectives for Masimo's stock. Their MASI share price forecasts range from $135.00 to $295.00. On average, they anticipate the company's share price to reach $188.00 in the next twelve months. This suggests a possible upside of 10.9% from the stock's current price. View analysts price targets for MASI or view top-rated stocks among Wall Street analysts. How have MASI shares performed in 2023? Masimo's stock was trading at $147.95 at the start of the year. Since then, MASI shares have increased by 14.5% and is now trading at $169.45. View the best growth stocks for 2023 here. When is Masimo's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 21st 2023. View our MASI earnings forecast. How were Masimo's earnings last quarter? Masimo Co. (NASDAQ:MASI) released its earnings results on Tuesday, November, 8th. The medical equipment provider reported $1.00 EPS for the quarter, beating the consensus estimate of $0.92 by $0.08. The medical equipment provider had revenue of $549.30 million for the quarter, compared to analysts' expectations of $533.96 million. Masimo had a trailing twelve-month return on equity of 18.04% and a net margin of 9.78%. What guidance has Masimo issued on next quarter's earnings? Masimo issued an update on its FY 2023 earnings guidance on Wednesday, December, 14th. The company provided EPS guidance of $4.25-$4.45 for the period, compared to the consensus estimate of $4.43. The company issued revenue guidance of $2.33 billion-$2.40 billion, compared to the consensus revenue estimate of $2.36 billion. What is Joe E. Kiani's approval rating as Masimo's CEO? 136 employees have rated Masimo Chief Executive Officer Joe E. Kiani on Glassdoor.com. Joe E. Kiani has an approval rating of 90% among the company's employees. What other stocks do shareholders of Masimo own? Based on aggregate information from My MarketBeat watchlists, some companies that other Masimo investors own include NVIDIA (NVDA), Netflix (NFLX), Shopify (SHOP), Okta (OKTA), PayPal (PYPL), Alibaba Group (BABA), Mastercard (MA), Trade Desk (TTD), Walt Disney (DIS) and Twilio (TWLO). What is Masimo's stock symbol? Masimo trades on the NASDAQ under the ticker symbol "MASI." Who are Masimo's major shareholders? Masimo's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Sumitomo Mitsui Trust Holdings Inc. (0.73%), Bank of Montreal Can (0.39%), Baillie Gifford & Co. (0.18%), New York State Common Retirement Fund (0.13%), New York State Teachers Retirement System (0.12%) and DekaBank Deutsche Girozentrale (0.10%). Insiders that own company stock include Adam Mikkelson, Anand Sampath, Bilal Muhsin, Craig B Reynolds, H Michael Cohen, Joe E Kiani, Jon Coleman, Micah W Young, Ramshorst David J Van, Tao Levy, Thomas Samuel Mcclenahan and Yongsam Lee. View institutional ownership trends. How do I buy shares of Masimo? Shares of MASI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Masimo's stock price today? One share of MASI stock can currently be purchased for approximately $169.45. How much money does Masimo make? Masimo (NASDAQ:MASI) has a market capitalization of $8.91 billion and generates $1.24 billion in revenue each year. The medical equipment provider earns $229.65 million in net income (profit) each year or $3.02 on an earnings per share basis. How many employees does Masimo have? The company employs 6,200 workers across the globe. How can I contact Masimo? Masimo's mailing address is 52 DISCOVERY, IRVINE CA, 92618. The official website for the company is www.masimo.com. The medical equipment provider can be reached via phone at (949) 297-7000, via email at ekammerman@masimo.com, or via fax at 949-297-7001. This page (NASDAQ:MASI) was last updated on 2/5/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.